Rate My Professor Chen Jiang

Dr. Chen Chen Jiang serves as a Senior Lecturer in the School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, at the University of Newcastle, Australia. She holds a Bachelor of Medicine from Bengbu Medical College in China, a Master of Applied Science in Biotechnology from the University of Western Sydney, and a PhD in Surgical Science from the University of Newcastle, completed in 2008. Her research interests center on translational cancer research, including adaptive mechanisms of cancer cells to endoplasmic reticulum (ER) stress, the role of chronic ER stress in treatment resistance, and interactions between cancer cells and the tumour microenvironment, with a particular emphasis on cancer-nerve crosstalk in cancer neuroscience. She investigates tumour ER stress as a trigger for tumour innervation and mechanisms regulating immune cell growth, phenotype, and function in cancer contexts. Her work also covers carcinogenesis, oncology, cancer cell death pathways, strategies to overcome treatment resistance in cancer cells, and signal transduction processes.

Dr. Jiang's career includes serving as an NHMRC Fellow in the School of Medicine and Public Health at the University of Newcastle from June 2011 to June 2015, and as a Career Development Fellow supported by the NHMRC Early Career Researcher fellowship, Cancer Institute NSW Career Development Fellowship, and fellowships from the University of Newcastle and Hunter Medical Research Institute. She has been honored with awards such as the Runner-up of Student Poster award from the Hunter Medical Research Institute in 2008, the Best research showcase award from the Faculty of Health at the University of Newcastle in 2008, the AACR Woman in Cancer Research Award from the American Association for Cancer Research in 2015, and the AACR Sanofi-Aventis Scholar-in-training Award in 2010. Notable publications include "Tumor innervation is triggered by endoplasmic reticulum stress" (Oncogene, 2022), "CCL2/CCR2 Expression in Locally Advanced Prostate Cancer and Patient Long-Term Outcome: 10-Year Results from the TROG 03.04 RADAR Trial" (Cancers, 2024), "Time to Introduce Nerve Density in Cancer Histopathologic Assessment" (Clinical Cancer Research, 2023), "Transcriptomics" (2022), and many others on ER stress, apoptosis, and cancer therapies. With over 47 grants totaling more than $6.6 million and supervision of eight PhD students to completion, her contributions significantly influence cancer research, particularly in understanding therapy resistance and tumour innervation.